GC
ACAD icon

Gruss & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Gruss & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-12,500
Closed -$310K – 41
2014
Q3 		$310K Buy
+12,500
New +$292K 0.38% 39

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gruss & Co's ACAD Position: Q4 2014 in Review

Gruss & Co sold out of Acadia Pharmaceuticals (ACAD) in Q4 2014, closing a stake of 12,500 shares — an estimated $310K sold.

Gruss & Co first reported a position in ACAD in Q3 2014 and held it in 1 quarter. The position peaked at $310K in Q3 2014. 182 funds tracked by Wall St. Rank hold ACAD as of Q4 2014.

  • Gruss & Co reported no remaining Acadia Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Gruss & Co sold 12,500 Acadia Pharmaceuticals shares in Q4 2014, an estimated $310K.
  • Gruss & Co first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Gruss & Co's Acadia Pharmaceuticals position peaked at $310K in Q3 2014.
  • 182 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2014.

Based on Gruss & Co's 13F filing for Q4 2014, filed 17 Feb 2015.